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L E T T E R  T O  T H E  E D I T O R
Risk of SARS-CoV-2 exposure in a hospital-based allergy 
practice
To the Editor,
The resumption of activity in hospital practices after COVID-19 
(SARS-CoV-2 infection) pandemic should be performed with the high-
est level of safety for both patients and healthcare professionals.1
The World Health Organization (WHO) declared COVID-19 pan-
demic on 11 March 2020 with temporary closures of medical spe-
cialties and cessation of many commercial activities still in effect to 
limit the spread of the disease.2 Spain is one of the European coun-
tries with the highest prevalence with 285,430 infected and almost 
27,100 deaths due to the disease as of 30 July 2020. Spain entered 
the so-called phase 1 of progressive transition to normality at the 
beginning of May, allowing more flexibility in confinement after the 
measures decreed by the central government.3
The reopening of hospitals’ specialties services also took place 
in this phase, including Allergy Services. For a safe reopening, it is 
necessary to know the prevalence of SARS-CoV-2 infection in pa-
tients seeking treatment for the first time after confinement.4 It is 
important to take into account that these patients may suffer from 
respiratory problems due to their allergic conditions such as asthma 
or rhinitis and that these could mask or mimic COVID-19 symptoms.2
To stratify the risk of contagion, we carried out a cross-sectional 
prevalence study of SARS-CoV-2 infection in patients and the prob-
ability to infect in an allergy practice after lockdown.
We carried out a monocentric, descriptive cross-sectional clinical 
research study in the Hospital Universitario Infanta Elena (Madrid). 
The first 100 patients that came to our Allergy Department and gave 
written consent to participate in the study were included between 
15 May and 15 June 2020. The prevalence in Madrid during that pe-
riod was either stable or declined slightly.3 SARS-CoV-2 arrest tests 
were carried out employing PCR (Hain Lifescience®) and IgM, IgG 
serological tests (Abbott®).5
The temperature was measured at arrival, and clinical data were 
extracted from patients’ medical histories. Questionnaires were per-
formed for descriptive signs and symptoms in the last 15 days to 
assess whether certain clinical features may influence the masking 
of COVID-19. The study protocol (PIC 086-20_HIE) was approved 
by the Clinical Research Ethics Committee of the Jiménez Díaz 
Foundation (Madrid, Spain).
The results obtained are shown in Table 1. The mean age of 
our population was 45, 2 ± 12.2 years, and 64% were women. 
All patients were asymptomatic on arrival at the consultation for 
COVID-19 symptoms, according to the questionnaire previously 
completed.
The majority of patients sought treatment for control of their re-
spiratory pathologies (asthma and rhinitis) (57%), drug allergy (28%) 
and skin allergy (12%).
The incidence of positive PCR tests was 3%, also, 3% showed 
IgM (+) and IgG (-); 12% of patients were IgM (+) and IgG (+), and 6% 
patients were IgM (-) IgG (+).One of the patients with positive PCR 
also had positive results for IgM and IgG. Twenty-four per cent of the 
patients tested presented positive markers of COVID-19.
None of the patients presented temperatures higher than 37ºC. 
Disclosed symptoms did not behave as good risk predictors. Thirty-
nine and 37% of the patients complained of cough and dyspnoea, 
respectively, in the last 15 days. Nine of them presented hyposmia, 
7% diarrhoea, 7% general discomfort and 3% fever. These symptoms 
were not statistically significant concerning positive PCR results, 
nor with the positive IgM results. One patient developed COVID-
19 symptoms afterwards. This fact differs from those observed in 
studies based on symptomatic patients, where dyspnoea, diarrhoea 
and headache had consistently high specificity across studies for di-
agnosing COVID-19. Only fever had high sensitivity across several 
studies.6
Positive laboratory tests were obtained in 14/55 asthmatic 
patients (25.5%); 3 of the 14 (21%) were PCR positive; and the re-
mainder were IgM+, IgG + or both. All of them denied symptoms. 
In patients that suffer rhinitis, the prevalence was 15.15% (10/66) 
Reviewing the results by the reasons of presentation to our allergy 
unit, we observed a positive PCR in 3 of the of 55 patients (5.26%) 
that complaint of respiratory allergic symptoms.
During the study period, 13,926 patients in Spain (0.03%) and 
9,527 in Madrid (0.14%) were diagnosed with positivity for SARS-
CoV-2 by molecular detection (PCR), and the prevalence was sta-
ble during that time.3 In our study, positive PCR involved 3% this 
means that the incidence of positive PCR tests for SARS-CoV-2 was 
statistically higher in our allergy practice than in general population 
(P = .001). The seroprevalence study of the central government has 
concluded that 11.7% of Madrid population has been infected with 
COVID-19. This data support that the prevalence in Madrid region 
double the number of Spain infected population (average 5.2%). 
Nevertheless, the seroprevalence in our study (21% of patients) was 
statistically higher than in general Madrid population (P = .001).
During the onset of symptoms, the serological antibody tests 
should not be used for diagnosing COVID-19 because of the low sensi-
tivity of the test over that first week. However, it might be useful if PCR 
tests are not available or have negative results.6 IgM is considered a 
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marker of current or recent infection, while IgG is considered a marker 
of past infection.7 We detected 3% of patients with IgM (+) IgG (-).
Being IgM positive does not mean they can transmit the disease, de-
tection of isolated SARS-CoV-2 IgM in asymptomatic individuals may 
not suppose a SARS-CoV-2 infection,8 although one of our patients 
with IgM+/IgG- developed COVID-19 symptoms afterwards. IgM is a 
very sensitive but less specific test and raises the possibility of current 
or recent infection but does not confirm it. On the other hand, due to 
the high specificity of PCR, if it was positive means they can transmit 
the disease, as the virus is actually there, probably, there is some data 
to suggest prolonged non-infectious shedding after the illness,9 as it 
could be our patient with positive PCR, IgM and IgG.
In our roles as allergists and health care providers, we must rec-
ognize the differences between allergic diseases and SARS-CoV-2, 
considering that the three PCR positive observed were patients 
consulting due to respiratory allergic symptoms. The reasons why 
patients consult may have varied due to the pandemic situation and 
the fear of going to the hospital. The prevalence of serological SARS-
CoV-2 in asthmatic patients was not statistically higher compared to 
the study group.
We have shown that there is a real risk of exposure to COVID-
19 during the visits to our Department. Prevention measures 
should be taken according to the type of intervention that is going 
to take place. Duration of visit, the distance between patient and 
clinicians, and the use or not of protective physical measures are 
variables that need to be considered.
We propose that during the consultation, practitioners should 
at least wear FFP2 masks and some form of eye guard protective 
glasses or face shield. As the spirometry is a procedure that gen-
erates aerosols, we take into consideration the recommendations 
of the Spanish society of allergy and immunology (SEAIC).10 They 
recommend the use of personal protection equipment such as FPP2 
or FPP3 masks, gloves, safety glasses and fluid repellent isolation 
gown.
To decrease the risk of transmission, of SARS-CoV-2, in hospi-
tal-based practices, it may be useful to perform serological and/or 
PCR tests in asymptomatic patients with respiratory diseases, pre-
vail to attendance.
Our results suggest that 3 of every 100 patients attended 
are suffering the infection when they visit the Hospital, so every 
Department must be aware of this issue.
As health centres begin to open again as before the closure, 
keep and take all possible precautions according to the local and 
state official guidelines is a necessary condition to reduce the risk of 
transmission of the disease among health care providers, staff and 
patients.
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TA B L E  1   Results of PCR and IgM, IgG serological tests
Total PCR + IgM+/IgG- IgM+/IgG+ IgM-/IgG+
Positives 
results (%)
Total 100 3 3 12 6 24 (24%)
Gender
Male 36 0 2 4 2 8 (22.2%)
Female 64 3 1 8 4 16 (25%)
Mean age (SD) 45.17 (15.2) 53.67 (12.2) 40 (18.2) 44.46 (15.85) 49.17 (15.85) 45 (15.5)
Asthma 55 3 1 6 4 14 (25.45%)
Rhinitis 66 2 0 5 3 10 (15.15%)
Propose os visit
Respiratory allergy 57 3 1 6 2 12 (21.05%)
Drug allergy 28 0 2 4 3 9 (32.14%)
Food allergy 2 0 0 0 0 0 (0%)
Skin allergy 12 0 0 2 1 3 (25%)
Hymenoptera 
allergy
1 0 0 0 0 0 (0)
Specific symptoms in the past 15 days
Fever 3 0 1 0 0 1 (33.3%)
Cough 39 2 0 2 1 5 (12.8%)
Diarrhoea 7 0 0 0 0 0 (0%)
Dyspnoea 37 1 0 0 0 1 (2.7%)
Hyposmia 9 1 0 1 0 2 (22.2%)
General discomfort 7 0 0 1 0 1 (14.3%)
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